ACG 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR

Lead author and member of the TARGET-NASH steering committee, A. Sidney Barritt IV, MD, MSCR, presented a new Target RWE study at ACG 2024 titled, “Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality.”

This video presentation explores the real-world impact of sodium-glucose cotransporter-2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors on patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Using data from the TARGET-NASH cohort, we investigate the association between these medications and key patient outcomes, including mortality and disease progression. Watch Dr. Barritt’s presentation of our latest insights.